טוען...
Biosimilar biological drugs in the treatment of inflammatory bowel diseases
Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflam...
שמור ב:
| הוצא לאור ב: | Prz Gastroenterol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Termedia Publishing House
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6983762/ https://ncbi.nlm.nih.gov/pubmed/31988667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2019.90093 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|